For the fourth-quarter last year, the company recorded revenues of $13.1 billion, an increase of four per cent compared with $12.6 billion for the same quarter in 2006. This is good news since the company lost US exclusivity for two key human health products - Norvasc and Zoloft - a loss that substantially dented revenue.

Margins have also been affected by foreign exchange, which increased revenues by approximately $610 million or five per cent, and the strong performance of many new and in-line products.

Animal Health revenues for the fourth-quarter 2007 were $785 million, an increase of two per cent compared with $655 million for the same period in 2006. For the full-year 2007, Animal Health revenues were $2.6 billion, an increase of 14 per cent compared with $2.3 billion in 2006. The growth is attributed to strong product performance, and a favourable foreign exchange, which bolstered revenues.

Key points:

• Fourth-Quarter 2007 Revenues of $13.1 Billion Increased from $12.6 Billion in the Year-Ago Quarter
• Fourth-Quarter 2007 Reported Diluted EPS of $0.42 Compared with $1.32 in the Year-Ago Quarter, which Included the $1.08 EPS Gain on the Sale of the Consumer Healthcare Business
• Fourth-Quarter 2007 Adjusted Diluted EPS(1) of $0.52 Increased from $0.43 in the Year-Ago Quarter
• Full-Year 2007 Revenues of $48.6 Billion Increased from $48.4 Billion in 2006